Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Significant Decrease in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 7,766 shares, a decline of 99.0% from the June 15th total of 802,784 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 285,814 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Trading Down 1.7%

Shares of Provectus Biopharmaceuticals stock traded down $0.00 during trading on Friday, reaching $0.07. 63,360 shares of the stock traded hands, compared to its average volume of 159,340. Provectus Biopharmaceuticals has a 52-week low of $0.04 and a 52-week high of $0.10. The business has a fifty day simple moving average of $0.07 and a two-hundred day simple moving average of $0.06.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.